POLYPEPTIDE GROUP AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.92 CHF | -4.24% |
|
+6.47% | +78.37% |
| Sales 2024 * | 35Cr 37Cr 33Cr 3.12TCr | Sales 2025 * | 41Cr 44Cr 39Cr 3.67TCr | Capitalization | 102.12Cr 109.23Cr 98Cr 9.13TCr |
|---|---|---|---|---|---|
| Net income 2024 * | -1.2Cr -1.28Cr -1.15Cr -107.25Cr | Net income 2025 * | 1.4Cr 1.5Cr 1.34Cr 125.12Cr | EV / Sales 2024 * | 3.13 x |
| Net Debt 2024 * | 7.36Cr 7.87Cr 7.05Cr 657.85Cr | Net Debt 2025 * | 12Cr 12Cr 11Cr 1.04TCr | EV / Sales 2025 * | 2.77 x |
| P/E ratio 2024 * |
-118
x | P/E ratio 2025 * |
60.3
x | Employees | 1,273 |
| Yield 2024 * |
-
| Yield 2025 * |
0.14% | Free-Float | 39.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on PolyPeptide Group AG
More press releases
More news
| 1 day | -4.24% | ||
| 1 week | +6.47% | ||
| Current month | -3.99% | ||
| 1 month | -3.25% | ||
| 3 months | +10.66% | ||
| 6 months | +81.26% | ||
| Current year | +78.37% |
1 week
29.95
32.15
1 month
28.7533.95
Current year
14.1934.60
1 year
14.1934.60
3 years
14.19145.02
5 years
14.19145.02
10 years
14.19145.02
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 12/23/12 | |
| Chief Tech/Sci/R&D Officer | 52 | 01/12/01 | |
Jens Fricke
COO | Chief Operating Officer | 59 | 01/22/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 01/21/01 | |
Peter Wilden
CHM | Chairman | 67 | 01/21/01 |
Jane Salik
BRD | Director/Board Member | 71 | 01/06/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/24/07 | 31.25 | +90.20% | 9 627 |
| 25/24/25 | 29.95 | -3.69% | 395 |
| 24/24/24 | 31.1 | -0.33% | 751 |
| 21/24/21 | 31.2 | -2.95% | 511 |
| 20/24/20 | 32.15 | +4.72% | 385 |
Delayed Quote London S.E., May 07, 2024 at 05:29 pm IST
More quotes
Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.
Sector
Pharmaceuticals
Calendar
13/08/2024
- Q2 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
30.98
EUR
Average target price
25.12
EUR
Spread / Average Target
-18.89%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +55.19% | 81TCr | |
| +45.57% | 65TCr | |
| -6.09% | 35TCr | |
| +21.92% | 34TCr | |
| +19.47% | 25TCr | |
| +3.68% | 23TCr | |
| +14.08% | 22TCr | |
| +10.86% | 17TCr | |
| -2.78% | 16TCr |
- Stock Market
- Equities
- PPGN Stock
- 0AAJ Stock
